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Cachexia, or wasting of skeletal muscle and fat, afflicts many patients with chronic
diseases including cancer, organ failure, and AIDS. Muscle wasting reduces quality
of life and decreases response to therapy. Cachexia is caused partly by elevated
inflammatory cytokines, including interleukin-6 (IL-6). Others and we have shown that
IL-6 alone is sufficient to induce cachexia both in vitro and in vivo. The mitogen-activated
protein/extracellular signal-regulated kinase kinase (MEK) inhibitor Selumetinib has been
tested in clinical trials for various cancers. Moreover, Selumetinib has also been shown
to inhibit the production of IL-6. In a retrospective analysis of a phase II clinical trial in
advanced cholangiocarcinoma, patients treated with Selumetinib experienced significant
gains in skeletal muscle vs. patients receiving standard therapy. However, the use of
Selumetinib as a treatment for cachexia has yet to be investigated mechanistically.
We sought to determine whether MEK inhibition could protect against cancer-induced
cachexia in mice. In vitro, Selumetinib induced C2C12 myotube hypertrophy and nuclear
accretion. Next we tested Selumetinib in the Lewis lung carcinoma (LLC) model of cancer
cachexia. Treatment with Selumetinib reduced tumor mass and reduced circulating and
tumor IL-6; however MEK inhibition did not preserve muscle mass. Similar wasting was
seen in limb muscles of Selumetinib and vehicle-treated LLC mice, while greater fat and
carcass weight loss was observed with Selumetinib treatment. As well, Selumetinib did
not block wasting in C2C12 myotubes treated with LLC serum. Taken together, out
results suggest that this MEK inhibitor is not protective in LLC cancer cachexia despite
lowering IL-6 levels, and further that it might exacerbate tumor-induced weight loss.
Differences from other studies might be disease, species or model-specific.
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INTRODUCTION
Cachexia is a devastating consequence of cancer and other
chronic diseases recognized by dysmetabolism leading to a
progressive reduction in skeletal muscle and adipose tissue
(Fearon et al., 2011; Argilés et al., 2015; Tsoli et al., 2016). Muscle
wasting reduces function, quality of life and decreases response to
therapy. Lowmuscle mass increases chemotherapy toxicity, while
chemotherapy in turn can cause muscle wasting and contribute
to cachexia (Chen et al., 2015; Barreto et al., 2016; de Lima Junior
et al., 2016; Toledo et al., 2016). Currently there are no approved,
effective therapies for cachexia. However, blocking muscle loss
in cancer cachexia prolongs function and life, indicating that
anti-cachexia therapies will be an essential adjunct to anti-tumor
therapies for treatment of cancer (Benny Klimek et al., 2010;
Zhou et al., 2010; Hatakeyama et al., 2016).
There are several underlying mechanisms that directly
contribute to cachexia. It has been referred to as a syndrome
of energy imbalance, where intake is decreased and expenditure
is increased. However, even with a controlled energy intake,
this imbalance persists (Evans et al., 1985). The loss of skeletal
muscle mass is largely attributed to abnormalities in protein
metabolism, where degradation outweighs synthesis caused in
part by increased activity of the ubiquitin-proteasome pathway
as well as autophagy (Acharyya and Guttridge, 2007; Mammucari
et al., 2007). Loss of myofibrillar proteins leads directly to muscle
atrophy, weakness, and fatigue. Common catabolic pathways
involved in turnover of skeletal muscle proteins are induced by
a multitude of inflammatory cytokines, both tumor- and host-
derived. These cachectic mediators include TNFα, Myostatin,
Activin, other members of the TGF-β superfamily, and the well-
known driver of cachexia, Interleukin-6 (IL-6) (Jackman and
Kandarian, 2004; Fearon et al., 2012; Tsoli and Robertson, 2013;
Narsale and Carson, 2014; Londhe and Guttridge, 2015). IL-6
binds IL-6 receptor and the common signaling receptor GP130
to activate the ERK, AKT, and STAT3 pathways (Belizário et al.,
2016). Others and we have shown that IL-6 alone is sufficient to
induce muscle wasting both in vitro and in vivo (Bonetto et al.,
2011, 2012; Zimmers et al., 2016), largely through activation of
STAT3 (Zimmers et al., 2016) downstream of GP130 and JAK.
Inhibition of IL-6, IL-6 receptor, or STAT3 all reduce cachexia in
experimental systems (Strassmann et al., 1992; Oldenburg et al.,
1993; White et al., 2011; Silva et al., 2015). Moreover, anti-IL-6
therapies have shown promise in human lung cancer cachexia
(Bayliss et al., 2011).
In addition to IL-6, a variety of mitogenic and inflammatory
stimuli can activate the Mitogen Activated Protein Kinase
(MAPK)/ERK pathway, including other cytokines and growth
factors signaling through tyrosine kinase receptors (Guan, 1994).
MEK1/2 phosphorylates ERK and influences survival, growth,
proliferation, and inflammatory processes (Zheng and Guan,
1993; Hommes et al., 2003). The MEK pathway is also activated
by oncogenic Ras, and has been targeted for anti-cancer therapies
(Neuzillet et al., 2014). The selective small molecule MEK1/2
inhibitor Selumetinib decreases phosphorylation and activation
of ERK1/2 (Yeh et al., 2007) and shows efficacy in cancers of
the lung, skin, ovary and liver (Miller et al., 2014; Facciorusso
et al., 2015; Heigener et al., 2015; Shoushtari and Carvajal,
2016).
A Phase II study of Selumetinib showed weight gain in
patients with bililary cancer, a condition typically associated
with severe wasting (Bekaii-Saab et al., 2011). Retrospective
re-analysis of those data showed that patients who received
Selumetinib experienced significant gains in skeletal muscle while
those on standard therapy experienced muscle loss (Bekaii-Saab
et al., 2011; Prado et al., 2012). Inhibition of the ERK pathway,
via a dominant negative form of Raf or a pharmacological
inhibitor, results in robust myotube hypertrophy (Rommel
et al., 1999). Additionally, ERK inhibition de-represses myogenic
differentiation caused by cardiotrophin-1, a member of the IL-
6 family of cytokines (Miyake et al., 2009). Pharmacological
inhibition of ERK1/2 significantly increases mRNA levels of the
transcription factor myogenin, promoting differentiation and
expression of muscle specific genes and the myogenic program
(Adi et al., 2002). Finally, ERK inhibition has also been shown to
prevent muscle wasting in a C26 colon carcinoma mouse model
of cancer cachexia (Penna et al., 2010; Quan-Jun et al., 2016).
Given the promising results of Selumetinib in patients and
of ERK inhibition in mice, we sought to investigate Selumetinib
in a LLC model of cancer-induced cachexia (Bennani-Baiti and
Walsh, 2011). Here we report in vitro hypertrophy and in vivo
tumor killing and inhibition of IL-6 production by Selumetinib
in mice, but no evidence of anti-cachexia effects either in vivo or
in vitro.
MATERIALS AND METHODS
Cell Cultures
Lewis lung carcinoma cells were maintained at low confluence
at 37◦C in a humidified atmosphere of 5% CO2 in DMEM, 10%
fetal bovine serum (FBS), 100 U/mL penicillin, and 100 mg/mL
streptomycin (pen/strep). Cells were trypsinized, counted and
resuspended in PBS for injection.
Murine C2C12 myoblasts (ATCC) were grown in DMEM,
10% FBS and pen/strep. Confluent cells were switched to
differentiation medium (DM), consisting of DMEM with 2%
horse serum and pen/strep for 96 h. After this time, the medium
was replaced with DM containing 10 nM Selumetinib or vehicle
for an additional 48 h. For the LLC plasma experiment, C2C12
cells were differentiated for 96 h before being switched to media
consisting of DMEM with 2% plasma from control or LLC
tumor bearing mice and pen/strep, either with or without 10nM
Selumetinib, then incubated for an additional 48 h.
Animals
All experimental animal protocols were approved by and used
in compliance with the Indiana University School of Medicine
Institutional Animal Care and Use Committee. Eight-week
old male C57BL/6J mice were obtained from The Jackson
Laboratory. All mice were maintained on a regular light-dark
cycle and allowed free access to food and water throughout
the duration of the experiment. Mice were grouped as follows:
Control + vehicle (n = 6), LLC + vehicle (n = 8), and LLC +
Selumetinib (n = 8). Tumor bearing mice were subcutaneously
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FIGURE 1 | Selumetinib induces myotube hypertrophy. (A) Western blotting analysis of C2C12 myotubes shows that 1 and 10 nM of Selumetinib reduced
phosphorylated ERK1/2. pERK1/2 was normalized to α-Tubulin. (B) Representative myotubes treated with 10 nM Selumetinib or vehicle and stained for myosin heavy
chain. Treatment with 10 nM Selumetinib induces myotube hypertrophy (+15.24%). Conditions were performed in triplicate. Data are means ± SEM. *p < 0.05,
**p < 0.01 vs. control.
FIGURE 2 | Selumetinib inhibits ERK phosphorylation in skeletal muscle in vivo. (A) Western blotting analysis of quadriceps lysates shows reduced pERK1/2
in Selumetinib treated mice, consistent with MEK inhibition. (B) Quantification of Western blotting analysis. pERK1/2 was significantly reduced in tumor bearing mice
treated with Selumetinib compared to vehicle treated control and tumor bearing mice, while total ERK1/2 was unchanged. Data are expressed as means ± SEM.
***p < 0.001 vs. Control + Vehicle, ###p < 0.001 vs. LLC + Vehicle.
injected with 106 LLC cells in the intrascapular region on day 0,
with treatments beginning 24 h later. Selumetinib (Selleckchem)
in vehicle (0.5%methylcellulose/0.2% Tween 80) or vehicle alone
was administered twice daily at 25 mg/kg by gavage (Shannon
et al., 2009; Troiani et al., 2012; Huang et al., 2013). Body
weights of the mice were recorded daily. Mice were euthanized
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FIGURE 3 | Selumetinib reduces IL-6 levels in blood and tumor, but not muscle. (A) Western blotting analysis shows quadriceps IL-6 was not changed in
cachexia or with Selumetinib. (B) IL-6 expression was reduced in lysates of tumors from mice treated with Selumetinib. Data are expressed as the means ± SEM. (C)
Representative images of immunohistochemistry. Selumetinib-treated mice show reduced staining for IL-6 in tumor. (D) Plasma IL-6 levels were increased in
vehicle-treated LLC mice. Selumetinib treated LLC mice showed a significant decrease in circulating IL-6 vs. vehicle-treated LLC mice. Data are expressed as
means ± SEM. *p < 0.05 vs. LLC + Vehicle; **p < 0.01 vs. control + Vehicle; ##p < 0.01 vs. LLC + Vehicle.
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FIGURE 4 | Selumetinib reduced tumor mass, but did not protect against cancer-induced cachexia. (A) Tumor mass was significantly reduced in mice
treated with Selumetinib. When compared to controls, LLC-bearing mice treated with either vehicle or Selumetinib showed similar wasting in the quadriceps (−11.86
and −11.08%,), gastrocnemius (−10.21 and −7.92%), and tibialis anterior muscles (−12.30 and −8.31%). Epididymal fat loss was significant in the LLC-Selumetinib
group. Greater carcass loss was observed in the LLC-Selumetinib mice, while heart loss was greater in vehicle-LLC mice. Data are expressed as means ± SEM.
*p = <0.05, **p = <0.01. (B) Representative images of muscle fiber cross-sectional area and quantification. Data are expressed as means ± SEM.
under general anesthesia on day 17 when some mice reached
the criteria for a humane endpoint. Muscles, tumors and organs
were dissected, weighed, snap frozen in liquid nitrogen, and
stored at −80◦C. Tissue weights are expressed as a percentage of
initial body weight to normalize for small differences in starting
size.
Immunofluorescence and
Immunohistochemistry
C2C12 cultures were fixed and permeabilized in ice cold
acetone/methanol (1:1) at −20◦C for 20 min. After 10 min of
rehydration in PBS at room temperature (RT), cells were blocked
in an 8% BSA solution for 1 h at RT. Primary antibody against
myosin heavy chain (Developmental Studies Hybridoma Bank)
was incubated overnight at 4◦C with gentle agitation. Washed
cultures were incubated with AlexaFluor 488-labeled anti-mouse
IgG (Life Technologies) for 1 h at RT. Nuclei were stained with
DAPI and images were captured on an Axio Observer.Z1 (Zeiss).
Myotube diameter was measured using ImageJ analysis software
(Wayne Rasband, U.S. National Institutes of Health).
For analysis of muscle fiber cross-sectional area, tibialis
anterior muscles were mounted on cork discs with Optimal
Cutting Temperature compound, and frozen in 2-methylbutane
cooled in liquid nitrogen before being stored at −80◦C. Fresh
frozen sections were cut using a Leica CM1860 Cryostat (Leica
Microsystems Inc.). Muscle sections were fixed in 100% acetone
at−20◦C before being rehydrated with PBS and blocked in an 8%
BSA solution for 1 h at RT. Following overnight incubation with
a primary antibody against Dystrophin (Vector Laboratories),
sections were incubated for 1 h at RT with an AlexaFluor 594-
labeled anti-mouse IgG. Muscle fiber cross-sectional area was
measured using an ImageJ macro developed by Dr. Richard
Lieber (Minamoto et al., 2007).
Formalin-fixed, paraffin-embedded tumor tissue sections were
deparaffinized in xylene and ethanol. Slides were boiled in 10
mM sodium citrate buffer pH 6.0 for 10 min, and cooled at
RT for 30min, then blocked with 8% BSA in PBS for 1 h,
followed by overnight incubation at 4◦C with antibody against
IL-6 (Abcam) or normal rabbit IgG (Santa Cruz Biotechnology).
Antibody detection used the ImmPRESS HFP Anti-Rabbit
IgG (Peroxidase) Polymer Detection kit and ImmPACT DAB
Peroxidase (HRP) Substrate per manufacturer’s instructions
(Vector Laboratories).
Western Blotting
Muscles and tumor were homogenized on ice in lysis buffer
containing 25 nM TrisHCl pH 7.6, 150 mM NaCl, 1% NP-40,
1% sodium deoxycholate, 0.1% SDS, and fresh protease and
phosphatase inhibitor cocktail tablets (Roche). Homogenates
were centrifuged at 4◦C at 14,000 rpm for 15min, and
supernatant was collected and stored at −80◦C. Protein
concentration was measured by BCA protein assay kit (Thermo
Scientific). Protein extracts (30 µg) were denatured at 95◦C for
5 min in loading buffer (125 mM Tris pH 6.8, 4% SDS, 20%
glycerol, 1% bromphenol blue, and 10% 2-mercaptoethanol).
Samples were resolved on Tris-Glycine gels and transferred
to nitrocellulose (Bio-Rad Laboratories). Membranes were
blocked in SEA BLOCK Blocking Buffer (Thermo Scientific)
and incubated overnight at 4◦C with antibodies against: IL-6
(EMD Millipore), α-Tubulin (Sigma-Aldrich), Phospho-p44/42
MAPK (ERK1/2) (Thr202/Tyr204), p44/42 MAPK (ERK1/2),
and GAPDH (Cell Signaling Technology). Anti-mouse and anti-
rabbit IgG conjugated to DyLight 680 and 800 fluorescent
dye (Cell Signaling Technology) respectively, were detection
antibodies incubated for 1 h at RT. Membranes were imaged and
quantified using an ODYSSEY CLx Infrared Imaging System and
software (LI-COR).
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FIGURE 5 | ERK inhibition does not block LLC plasma-induced atrophy. C2C12 myotubes were treated with control plasma, control plasma + 10 nM
Selumetinib, LLC plasma, or LLC plasma + 10 nM Selumetinib. Each data point represents myotubes treated with plasma from one individual mouse. (A) Western
(Continued)
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FIGURE 5 | Continued
blotting analysis of C2C12 myotubes incubated with control (−50.71%) or LLC plasma (−55.55%) show inhibition of ERK1/2 phosphorylation upon treatment with
Selumetinib. Data are expressed as means ± SEM. ****p = <0.0001. (B) Representative images and quantification of myotube diameter of C2C12 cells. Myotubes
incubated with control plasma and treated with Selumetinib showed significant hypertrophy (+20.30%) vs. the control plasma only group. Both the LLC plasma only
(−10.57%) and the LLC plasma with Selumetinib (−13.94%) groups showed atrophy vs. control plasma only. Data are expressed as means ± SEM. *p = <0.05,
**p = <0.01, ***p = <0.001. (C) Representative images and quantification of nuclei per fiber. The total number of fibers counted were the same amongst all groups.
Selumetinib treatment increased nuclei per fiber (+25.14%) when compared to control plasma only. LLC plasma showed a decrease (−11.67%) vs. control plasma
only, which Selumetinib treatment was unable to block (−12.22%), although these were not statistically significant. Data are expressed as means ± SEM.
***p = <0.001.
IL6 Immunoassay
Whole blood was collected at euthanasia, via cardiac puncture,
into EDTA tubes (BD Biosciences) and placed on ice. Plasma was
separated by centrifugation at 3500 × rpm for 15 min at 4◦C
and stored at −80◦C. IL-6 was detected in duplicate samples by
a mouse magnetic 1-plex custom kit as per the manufacturer’s
instructions (Life Technologies) on a MAGPIX (Luminex).
Data Analysis
For experiments containing only two groups, statistical testing
was by unpaired t-test. Experiments containing three or more
groups, statistical significance was determined by one-way
analysis of variance (ANOVA), followed by Tukey’s multiple
comparisons test. A p-value > 0.05 was considered statistically
significant.
RESULTS
Selumetinib Induced C2C12 Hypertrophy
C2C12 myoblasts proliferate as mononuclear cells in growth
medium, and are induced to differentiate into syncytial myotubes
upon switching to low serum conditions. This system has been
used extensively to assess the atrophic or hypertrophic effects
of proteins, conditioned medium, serum, or small molecules
(Bonetto et al., 2011, 2012). Differentiated C2C12 myotubes
were incubated with Selumetinib or vehicle for 48 h, with a
media change after the first 24 h. Western blotting showed that
1 and 10 nM Selumetinib reduced ERK1/2 phosphorylation in
C2C12 myotubes by ∼30% (Figure 1A). Myotube hypertrophy
(diameter +15.42%, P < 0.05) was observed at a concentration
of 10 nM but not 1 nM Selumetinib (Figure 1B), and higher
concentrations were toxic (data not shown).
Selumetinib Inhibited ERK1/2
Phosphorylation in Skeletal Muscle
To test effects of Selumetinib on tumor growth and body
composition in the setting of cancer, we injected mice with LLC
cells, a well-validated and traditional model of cancer cachexia.
Mice were treated twice daily with 25mg/kg Selumetinib by
gavage. Control mice received PBS injection and vehicle gavage,
while tumor-bearing mice received tumor cell injection and
vehicle gavage. No differences in overall body weight change
or body composition were observed over the course of the
experiment (data not shown). Mice were euthanized and
necropsied on day 17. To query an on-target effect of Selumetinib
in muscle, we performed Western blotting for phospho-ERK1/2.
pERK1/2 was decreased 73.31 and 74.03% in the quadriceps of
Selumetinib-treated mice vs. vehicle-treated control and tumor-
bearing mice respectively (Figures 2A,B, P < 0.001). Total
ERK1/2 was similar among all groups (Figures 2A,B).
IL-6 Expression Decreased in Blood and
Tumor, but Not Muscle
Given that Selumetinib reportedly blocks production of the
pro-cachectic inflammatory cytokine IL-6 (Tai et al., 2007),
we measured IL-6 in tissue, tumor and blood. By Western
blotting, IL-6 was not decreased in skeletal muscle (Figure 3A).
However, Selumetinib decreased IL-6 protein by 35.04%
(P < 0.05) in tumor lysates (Figure 3B), a finding confirmed
by immunohistochemistry of tumor sections (Figure 3C).
Furthermore, circulating levels of IL-6 were decreased 80.80%
(P < 0.01) in Selumetinib-treated LLC mice vs. vehicle-treated
tumor bearers (Figure 3D). IL-6 levels in the Selumetinib group
were not significantly different from non-tumor bearing mice.
Selumetinib Reduced Tumor Size, but Did
Not Prevent Muscle Wasting or Fat Loss
Consistent with its anti-tumor effects in other models of non-
small cell lung cancer, Selumetinib treatment reduced LLC tumor
size by 43.18% (P < 0.01) (Figure 4). Given that tumor size was
greatly reduced, we expected muscle wasting to be attenuated,
because in this model severity of cachexia generally correlates
with tumor burden. However, in all muscles analyzed, both
the Selumetinib and vehicle-treated LLC mice showed similar
wasting (Figure 4A). Analysis of muscle fiber cross-sectional area
displayed the same pattern as those observed in the muscle
weights (Figure 4B). Greater fat loss and carcass loss were
observed in Selumetinib-treated mice (Figure 4A).
Selumetinib Did Not Prevent LLC
Plasma-Induced C2C12 Myotube Atrophy
While a reduced tumor burden and decreased circulating levels
of IL-6 were seen with Selumetinib treatment, we did not
observe any protection in skeletal muscle or fat mass. This led
us to question whether there were other cachexia drivers in
the LLC model that Selumetinib treatment could not modulate.
To explore this, we treated C2C12 myotubes with plasma from
either control mice or vehicle treated tumor bearing mice. This
was done both with and without 10 nM of Selumetinib, the
concentration previously used to induce myotube hypertrophy.
Western blotting analysis showed that Selumetinib was able to
reduce expression of pERK1/2 50.71 and 55.55% in myotubes
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incubated with control or LLC plasma, respectively (Figure 5A).
Consistent with our prior in vitro data (Figure 1), Selumetinib
treatment was able to induce significant hypertrophy inmyotubes
incubated with control plasma. However, similar to our in
vivo results, Selumetinib was unable to block myotube wasting
induced by LLC plasma (Figure 5B). Further analysis showed
that in addition to increasing myotube diameter, ERK inhibition
also increased the number of nuclei per fiber (Figure 5C).
Myotubes treated with LLC plasma showed a reduction in the
number of nuclei per fiber, although this was not statistically
significant, which Selumetinib treatment was again unable to
attenuate.
DISCUSSION
Here we show that unlike results reported in patients with biliary
cancers, mice with lung cancer do not exhibit reduced lean
muscle loss despite tumor response with Selumetinib. This result
was surprising for three reasons. Firstly, Selumetinib increased
C2C12 fiber size in vitro, suggesting a potential pro-anabolic
effect in skeletal muscle. In addition, we observed an increase
in the number of nuclei per fiber with Selumetinib, suggesting
that ERK inhibition increased the differentiation or fusion
potential of myoblasts. However, despite reducing pERK1/2 in
skeletal muscle, Selumetinib did not result in muscle protection
much less hypertrophy in LLC conditions. Secondly, Selumetinib
significantly inhibited tumor growth. Tumor mass normally
correlates with the severity of muscle wasting, thus reduction of
tumor burden should have led secondarily to reduced cachexia.
This disconnect between tumor size and cachexia suggests
that Selumetinib actually enhanced pro-cachectic pathways in
LLC mice. Thirdly, those pathways must also be independent
of IL-6, given that circulating and tumor-derived IL-6 were
reduced in our study. This conclusion is supported by the
observation that Selumetinib was unable to block LLC plasma-
induced myotube atrophy. These data suggest that another, or
several other, inflammatory cytokines or circulating factors are
the essential driver/s of muscle wasting in the LLC model,
not IL-6.
It is possible that the effects of Selumetinib on tumor growth
and muscle wasting are disease specific, because Selumetinib
was associated with increased lean body mass in patients with
biliary cancers (Prado et al., 2012) and in the murine C26 colon
adenoma cachexia model. Biliary, colon and lung cancers might
exert muscle wasting through different effectors. In the C26
studies, ERK inhibition had no effect on tumor mass in one
study (Penna et al., 2010), but resulted in an ∼15% decrease in
tumor mass in another study (Quan-Jun et al., 2016). However,
the studies each used different inhibitors and the mice from both
were of a different genetic background than those used here.
The MEK pathway might also play different roles in humans
vs. murine cancer cachexia. In the phase II clinical trial, 52% of
patients treated with Selumetinib experienced a decrease in target
lesion size, similar to what we observed in the present study. This
could potentially explain the gain in total body mass of patients
treated with Selumetinib, as opposed to the loss in patients
receiving standard therapy. The increased muscle mass could be
a result of a reduced tumor burden, and not any direct effect
on the skeletal muscle itself. The authors hypothesize that the
anabolic effect of Selumetinib is likely attributed to the inhibition
of cytokine secretion. However, here we observed a significant
decrease in both tumor tissue and circulating levels of IL-6, but
with no beneficial effects on skeletal muscle.
Finally, it is possible that the lack of muscle preservation
is due to the differential regulation and requirements of the
MEK pathway during myogenesis. While we did not investigate
muscle satellite cells in this study, it is possible that constant
inhibition of the pathway led to a defect in proliferation
or depletion of the satellite cell pool. Literature shows that
ERK signaling can be both stimulatory and inhibitory for
muscle differentiation. ERK1/2 activation is necessary for satellite
cell proliferation and self-renewal (Ogura et al., 2015; Hindi
and Kumar, 2016), but not required for fusion or expression
of muscle specific genes (Jones et al., 2001). In addition,
ERK2 is necessary for myotube formation, as siRNA-mediated
knockdown of ERK2 in C2C12 myoblasts inhibited their fusion
into multinucleated myotubes (Li and Johnson, 2006). Akt
activation, a positive regulator of muscle mass, leads to inhibition
of the MEK pathway in differentiated myotubes, while having
no effect on their muscle precursor cells (Rommel et al., 1999).
Conversely, leukemia inhibitory factor, an IL-6 family cytokine,
inhibits myogenic differentiation through phosphorylation and
activation of ERK1/2 (Jo et al., 2005). In vitro data show
that early ERK1/2 activation, within 24 h post differentiation
induction, can repress myogenic differentiation. Inhibition of
MEK1 in the latter stages of differentiation displayed similar
effects, blocking myotube formation (Jo et al., 2009). These
data suggest that myogenic differentiation is coordinated by
low MEK1 activity during the initial phases, and high activity
thereafter. As such, while constant administration of Selumetinib
inhibits tumor growth, achieving an anabolic effect appears to be
more complicated.
Due to the requirements for ERK1/2 modulation in
myogenesis, constant inhibition of ERK1/2 may be detrimental
to skeletal muscle mass. The studies mentioned were able
to control the myogenic stages at which the pathway was
perturbed. While this would be challenging to accomplish in
vivo, a potential approach would be to treat intermittently.
This approach would allow for pathway activation, instead of
remaining under a constant state of inhibition. Based upon
the literature, allowing for cycles of activation and inhibition
could potentially produce the stimulatory effects necessary for
muscle hypertrophy. Future investigation will be necessary to
determine a proper dosing regimen in order to determine
the therapeutic potential of ERK inhibition as a treatment for
cachexia and the potential effects of such cyclic dosing on tumor
growth.
Taken together, these data suggest the need to consider the
differential regulation of not only the MEK and IL-6 pathways,
but also other pathways in muscle wasting of cancer cachexia.
Moreover, they point to profoundly different drug-responsive
phenotypes in commonly used cachexia models, suggesting
diversity in the underlying cellular and molecular mechanisms
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and the need for care in extrapolating results across disease states,
clinical trials and model systems.
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